Welcome to our dedicated page for EMMAUS LIFE SCIENCES news (Ticker: EMMA), a resource for investors and traders seeking the latest updates and insights on EMMAUS LIFE SCIENCES stock.
Emmaus Life Sciences develops, markets, and sells biopharmaceutical therapies focused on sickle cell disease, led by Endari® (prescription-grade L-glutamine oral powder). News about EMMA commonly covers financial results, Endari commercialization, FDA labeling activity, competition from generic L-glutamine, and sales trends across the U.S. and international markets.
Company updates also address market access and distribution strategy for Endari, including activity in the Middle East and North Africa region and Saudi Arabia. Emmaus reports operating expenses, liquidity, and other financial items alongside product safety and indication information for Endari, which is approved to reduce acute complications of sickle cell disease in adult and pediatric patients five years of age and older.
Emmaus Life Sciences (OTCQB: EMMA) announced an exclusive option agreement with Cedars-Sinai to further evaluate L-glutamine oral powder in combination with chemotherapy as a potential treatment for Pancreatic Ductal Adenocarcinoma (PDAC). The work builds on the GlutaPanc trial (NCT04634539), recently published in Nature Cancer, and aims to assess efficacy and safety in patients with pancreatic cancer, an area of significant unmet medical need. According to Emmaus, the collaboration leverages Cedars-Sinai’s oncology research capabilities and Emmaus’ drug development experience. The company cautions that the safety and efficacy of L-glutamine for PDAC are not established and there is no guarantee of regulatory approval.
Emmaus Life Sciences (OTCQB: EMMA) reported results for the three and six months ended June 30, 2026, highlighted by its license and exclusive distribution agreement with NeoImmuneTech (NIT), effective May 15, 2026. Emmaus granted NIT exclusive rights to market, sell and distribute Endari in the U.S., its territories and possessions, and Canada in exchange for an upfront payment and sales-based royalties.
Net revenues for Q2 2026 rose 124% to $6.3 million from $2.8 million, mainly from recognition of NIT-related revenue, partly offset by lower direct Endari sales. Operating expenses fell to $2.1 million from $3.0 million following transfer of the sales force to NIT, driving income from operations of $3.8 million versus a $0.4 million loss a year earlier. Other expense increased to $2.5 million from $1.4 million, and net income reached $1.3 million, or $0.02 per share, compared with a $1.1 million net loss, or ($0.02) per share.
For the first half of 2026, net revenues were $8.3 million versus $5.2 million, with income from operations of $3.0 million versus a $1.4 million loss. The company reported a six‑month net loss of $2.0 million, improved from a $3.5 million loss in 2025. As of June 30, 2026, Emmaus had $2.8 million in cash and cash equivalents, total assets of $16.4 million, total liabilities of $82.5 million and a stockholders’ deficit of $66.2 million.
Emmaus Life Sciences (OTCQB: EMMA) reported Q1 2026 results, showing an 18% decline in net revenues to $2.0 million versus $2.4 million in Q1 2025, mainly from a 33% drop in U.S. sales amid generic L-Glutamine competition, partially offset by a 94% MENA sales increase.
Operating expenses fell to $2.6 million from $3.2 million, improving loss from operations to $0.8 million from $1.0 million. Other expense rose to $2.3 million from $1.3 million, driving a higher net loss of $3.3 million ($0.05 per share) versus $2.3 million ($0.04 per share). Cash and equivalents declined to $1.1 million from $2.1 million at year-end 2025.
Emmaus Life Sciences (OTCQB: EMMA) reported results for the year ended December 31, 2025. Net revenues fell 25% to $12.5 million from $16.7 million in 2024, driven by U.S. generic competition and partially offset by higher MENA sales. Operating expenses declined 34% to $11.4 million, producing income from operations of $0.2 million versus a $1.9 million loss in 2024. Other expense rose to $7.5 million, and net loss widened to $7.2 million, or $0.11 per share, on ~64.0 million weighted-average shares. Cash and equivalents increased to $2.1 million at year-end.
Emmaus Life Sciences (OTCQB: EMMA) entered a License and Exclusive Distribution Agreement with NeoImmuneTech (KOSDAQ:950220) for Endari® (prescription L-glutamine oral powder) in the U.S., U.S. territories, and Canada.
Under the deal Emmaus granted NIT exclusive rights to market, sell and distribute Endari and any generic equivalents in those territories in exchange for an upfront payment and royalties on NIT’s product sales. The agreement’s effective date is conditioned on NIT obtaining required regulatory approvals and licenses.
Emmaus said it will prioritize growth in other regions (Middle East, Brazil, Europe) while NIT cited synergies for commercializing its pipeline, including NT-I7.
Emmaus Life Sciences (OTCQB: EMMA) reported results for the three months ended September 30, 2025. Net revenues fell to $3.4 million from $5.5 million a year earlier, a 38% decline, driven by U.S. competition from generic L‑Glutamine and lower MENA sales timing. Operating expenses decreased to $2.4 million from $4.3 million, a 43% reduction, yielding income from operations of $0.7 million vs. $0.8 million prior year. Other expense increased to $2.2 million, producing a net loss of $2.1 million (≈$0.03 per share). Cash and cash equivalents were $0.3 million at September 30, 2025, down from $1.4 million at December 31, 2024.
Emmaus Life Sciences (OTCQB: EMMA), a biopharmaceutical company focused on sickle cell disease treatment, reported challenging Q2 2025 financial results. The company experienced a significant 48% decline in net revenue to $2.8 million compared to $5.4 million in Q2 2024, primarily due to generic L-Glutamine competition.
The company reported a net loss of $1.1 million ($0.02 per share), an improvement from the $2.2 million loss in Q2 2024. Operating expenses decreased by 33% to $3.0 million following workforce reductions. Cash position weakened to $0.9 million as of June 30, 2025, down from $1.4 million at year-end 2024.
Emmaus Life Sciences (OTCQB: EMMA) has received FDA approval for enhanced labeling of Endari®, their sickle cell disease treatment. The updated label incorporates new pharmacokinetic study data, providing additional prescribing information that confirms weight-based dosing, demonstrates no unwanted accumulation with twice-daily dosing, and validates administration flexibility with or without food.
Endari® maintains its FDA approval status for reducing acute complications of sickle cell disease in both adult and pediatric patients aged five years and older.
Emmaus Life Sciences (OTCQB: EMMA), a biopharmaceutical company focused on sickle cell disease treatment, reported its Q1 2025 financial results. Net revenues were $2.4 million, slightly down from $2.5 million in Q1 2024, due to competition from generic L-Glutamine. Operating expenses decreased to $3.2 million from $5.0 million, primarily due to Q4 2024 workforce reductions.
The company improved its loss from operations to $1.0 million from $2.7 million year-over-year. Net loss decreased to $2.3 million ($0.04 per share) from $4.3 million ($0.07 per share) in Q1 2024. Cash and cash equivalents stood at $1.3 million as of March 31, 2025.
Emmaus Life Sciences (OTCQB: EMMA) reported its 2024 financial results, showing significant challenges throughout the year. The company experienced a 43.6% decline in net revenues to $16.7 million (vs $29.6 million in 2023), primarily due to inventory shortages during early to Q3 2024.
Despite reducing operating expenses by nearly 30% to $17.3 million through decreased headcount and suspended R&D activities, the company recorded a loss from operations of $1.9 million compared to an income of $3.5 million in 2023. The net loss increased to $6.5 million ($0.10 per share) from $3.7 million ($0.07 per share) in 2023.
Cash position decreased to $1.4 million by year-end 2024, down from $2.5 million in 2023. Management expects 2025 revenues to reach or exceed 2024 levels, citing sufficient inventory for the year barring unexpected developments.